Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma

Lei Zhuang, Tianfu Wen, Mingqing Xu, Jiayin Yang, Wentao Wang, Hong Wu, Yong Zeng, Lvnan Yan, Yonggang Wei, Bo Li

Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China

Submitted: 31 December 2015
Accepted: 23 August 2016

Arch Med Sci 2017; 13, 6: 1383–1393
DOI: https://doi.org/10.5114/aoms.2017.71066
Copyright © 2017 Termedia & Banach

Abstract

Introduction: Guidelines based on the Barcelona Clinic Liver Cancer (BCLC) classification system recommend that hepatic resection should be performed only in patients in BCLC stage A. Patients with stage B or stage C should receive palliative or no treatment. However, actual clinical practice varies, and a recent analysis of hepatocellular carcinoma (HCC) surgery outcomes in high volume surgical centers throughout the world concluded that hepatectomy can provide survival benefit for selected patients in all three BCLC stages. The aim of this study is to evaluate the efficacy and tolerability of adjuvant sorafenib after hepatic resection in patients with intermediate-stage and advanced HCC.

Material and methods: In a retrospective case-control study involving 81 patients with intermediate/advanced HCC, 27 who received sorafenib 400 mg BID (median duration 7.33 months) following hepatic resection were compared with a matched group of 54 patients who received hepatic resection only. Overall survival (OS) and time to recurrence (TTR) were evaluated over a median follow-up time of 14.5 months.

Results: The median OS was significantly longer in the surgery+sorafenib group than in the surgery-only group (18.6 vs. 11.9 months; respectively; \( p = 0.014 \)). However, the median TTR did not differ significantly between the 2 groups (\( p = 0.291 \)).

Conclusions: Sorafenib is effective as adjuvant therapy after liver resection in intermediate-stage and advanced HCC, and can be considered a viable treatment option following surgery in such patients.

Key words: carcinoma, hepatocellular, hepatectomy, sorafenib.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and the third most common cause of cancer-related deaths [1]. Because of the high prevalence of hepatitis B virus (HBV) infection in China, HCC has a particularly high incidence in the Chinese population [2]. Treatment of HCC is complex because of the need to destroy tumor cells while at the same time preserving the often compromised liver function.

Guidelines based on the Barcelona Clinic Liver Cancer (BCLC) classification system [3–5] recommend that hepatic resection should be per-
formed only in patients in BCLC stage A, that is, only in those with small, single tumors and no signs or symptoms of liver dysfunction. Patients with multiple or large tumors (stage B) or those with symptomatic or invasive tumors (stage C) should receive palliative or no treatment [6, 7]. However, actual clinical practice varies, and a recent analysis of HCC surgery outcomes in high volume surgical centers throughout the world concluded that heparctomy can provide survival benefit for selected patients in all three BCLC stages [8].

Current BCLC-recommended treatments are not those currently applied in Asia-Pacific region countries such as China, Korea and Japan [9–12]. In the treatment algorithms used in the Asia-Pacific region, where radical resection is impractical, palliative resection combined with comprehensive therapy can be considered as a treatment option in patients with intermediate-stage and advanced HCC (BCLC stage B and stage C), even in the presence of poor prognostic factors such as venous and/or bile duct tumor thrombi or hilar lymph node metastasis. Survival benefits for this type of therapy have been reported in a broad group of such patients, although their outcome is inferior to the outcome of patients who do not have portal hypertension or have only single tumors [8, 13–17].

Sorafenib is an oral multikinase inhibitor that blocks tumor cell proliferation and angiogenesis by inhibiting the serine/threonine kinases Raf-1/B-Raf, and the tyrosine kinases of vascular endothelial growth factor receptor (VEGFR-2/-3) and platelet-derived growth factor receptor (PDGFR) [18]. In patients with advanced HCC, sorafenib therapy has produced significant improvement in the time to progression (TTP) and overall survival (OS) [19, 20].

As treatment outcomes with sorafenib therapy following hepatic resection in patients with intermediate-stage and advanced HCC are not yet known, we performed a retrospective, case-control study in HCC patients who were treated with or without adjuvant sorafenib therapy following surgery. The aim of the study was to evaluate the effectiveness and safety of adjuvant sorafenib in patients receiving surgery + sorafenib by comparing them with a matching group of patients treated with surgery alone.

**Material and methods**

**Study design and patients**

This single-center, retrospective, case-control study was performed at West China Hospital, Sichuan, China. Relevant data were retrieved from the patients’ clinical records, including medical history, laboratory results, radiologic findings, histology results, treatments and survival data, as well as the dosage and adverse events of adjuvant sorafenib therapy administered between January 2010 and June 2012. Patient status data (alive vs. deceased vs. progression) were collected periodically until the last follow-up day of the study, which was September 30, 2013.

**Surgery + sorafenib group**

We identified a total of 72 patients with histologically confirmed HCC who had received adjuvant sorafenib therapy following hepatic resection. Patients meeting the following criteria were eligible for inclusion in the study: liver tumor(s) classified as BCLC stage B or C, as confirmed by intraoperative ultrasound or postoperative pathology; no visible residual tumor on a computed tomography (CT) or magnetic resonance imaging (MRI) scan (as assessed by local radiological review) performed > 2 weeks after surgery; and no documented tumor recurrences evident on a CT or MRI scan performed prior to commencement of sorafenib therapy.

Patients who had previously received or were concomitantly receiving molecular targeted therapies or any other systemic treatment, those who had received a liver transplant at any time, those whose disease had progressed prior to sorafenib therapy, those with a secondary malignancy, and those with missing data were excluded from the analysis. In the event of drug-related adverse events, treatment interruptions or dosage reductions of sorafenib from 400 mg BID to 200 mg BID or to 200 mg BID, every alternate day was permitted. If further dosage reductions were required, patients were excluded from the study. The number of patients excluded on the basis of each exclusion criterion is shown in the flow chart in Figure 1.

**Surgery only group**

A 2 : 1 matched control group was created from patients who had undergone non-radical resection without sorafenib therapy during the same time period (Figure 1). The control group was matched for gender, presence of liver cirrhosis, BCLC stage, liver function (Child-Pugh class), transarterial chemoembolization (TACE) treatment, and diagnosis.

**Treatment**

**Surgery**

The extent of hepatic resection was defined according to Couinaud’s classification of liver anatomy. Major hepatectomy was defined as resection of 3 or more segments, while minor hepatectomy was the resection of fewer than 3 segments.
Sorafenib treatment

An initial sorafenib dosage of 400 mg was administered orally twice daily. Subsequently, discontinuations and dosage reductions of sorafenib were based on tolerance. Treatment was continued until clinical disease progression or unacceptable drug-related toxicity occurred.

Patients in both the sorafenib + surgery and surgery-only groups did not receive any other therapy after surgery except TACE.

BCLC classification

The following categories were used to classify patients:

• Stage B HCC: presence of 2 to 3 tumors, at least 1 of which was more than 3 cm in diameter; or more than 3 tumors of any diameter.
• Stage C HCC: any tumor with radiologically evident and histologically proven macrovascular invasion (portal vein, hepatic vein, inferior vena cava).

Outcome assessment

The patients’ clinical, laboratory, and radiologic records were reviewed independently by several investigators. The primary endpoints of the study were OS and time to recurrence (TTR). The patients’ survival duration was calculated from the date of surgery to death or study closure, while TTR was calculated from the date of surgery to radiologic recurrence or metastasis. Outcomes were also assessed in BCLC stage B and C subgroups of the 2 patient groups.

The secondary endpoint of the study was safety. Adverse events (AEs) of sorafenib were classified according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. [21].

Statistical analysis

Continuous data are presented as means and standard deviations, and categorical data as counts and percentages. Because matched data were used, the linear mixed model or generalized estimating equations (GEE) were used to compare the differences between the surgery + sorafenib and surgery-only groups. Kaplan-Meier curves with log-rank tests were performed to compare OS and TTR between the two treatment groups. Univariate and multivariate Cox proportional hazard models were performed to detect factors affecting survival and recurrence. Factors significantly affecting overall survival in univariate analyses were included in multivariate analyses. Adverse events were compared using Fisher’s exact test. A two-tailed \( p \)-value < 0.05 was considered statistically significant. Statistical analyses were performed using SAS 9.2 statistics software (SAS Inc., Cary, NC, USA).

Results

Patients

Demographic and clinicopathological characteristics of patients are shown in Table I. Twenty-seven patients were included in the surgery + sorafenib group and 54 matched patients were included in the surgery-only group. None of the patient characteristics showed any statistically significant difference between the 2 groups. The predominant cause of the underlying liver disease was HBV infection, which was found in 23 (85.2%) patients in the surgery + sorafenib group and 48 (88.9%) patients in the surgery-only group. No patients in either group had HCV infection. All patients were rated as Child-Pugh class A at baseline, a classification reflecting well-preserved liver function.
Table I. Demographic and clinicopathological characteristics of patients

| Variable                              | Surgery + sorafenib group (n = 27) | Surgery-only group (n = 54) | P-value |
|---------------------------------------|------------------------------------|-----------------------------|---------|
| Age, mean ± SD [years]                | 48.2 ±9.7                          | 49.4 ±9.4                   | 0.450   |
| Gender:                               |                                    |                             |         |
| Male                                  | 25 (92.6%)                         | 50 (92.6%)                  | 1.000   |
| Female                                | 2 (7.4%)                           | 4 (7.4%)                    |         |
| Viral hepatitis status:               |                                    |                             |         |
| HBV                                   | 23 (85.2%)                         | 48 (88.9%)                  | 0.206   |
| Unknown                               | 4 (14.8%)                          | 6 (11.1%)                   |         |
| Preoperative AFP:                     |                                    |                             |         |
| < 400 ng/ml                           | 12 (44.4%)                         | 15 (27.8%)                  | 0.195   |
| ≥ 400 ng/ml                           | 15 (55.6%)                         | 39 (72.2%)                  |         |
| Liver cirrhosis:                      |                                    |                             |         |
| No                                    | 6 (22.2%)                          | 12 (22.2%)                  | 1.000   |
| Yes                                   | 21 (77.8%)                         | 42 (77.8%)                  |         |
| ECOG performance status score:        |                                    |                             |         |
| 0                                     | 12 (44.4%)                         | 35 (64.8%)                  | 0.076   |
| 1                                     | 15 (55.56%)                        | 19 (35.19%)                 |         |
| BCLC stage:                           |                                    |                             |         |
| B                                     | 12 (44.4%)                         | 24 (44.4%)                  | 1.000   |
| C                                     | 15 (55.6%)                         | 30 (55.6%)                  |         |
| Number of tumors:                     |                                    |                             |         |
| < 3                                   | 15 (55.6%)                         | 33 (61.1%)                  | 0.739   |
| ≥ 3                                   | 12 (44.4%)                         | 21 (38.9%)                  |         |
| Tumor size, mean ± SD [cm]            | 7.8 ±3.9                           | 8.4 ±3.5                    |         |
| Resection extent:                     |                                    |                             | 0.788   |
| Minor                                 | 8 (29.6%)                          | 18 (33.3%)                  |         |
| Major                                 | 19 (70.7%)                         | 36 (66.7%)                  |         |
| Tumor differentiation:                |                                    |                             |         |
| Poor                                  | 19 (70.4%)                         | 36 (66.7%)                  | 0.839   |
| Moderate                              | 8 (29.6%)                          | 18 (33.3%)                  |         |
| Cause of death:                       |                                    |                             | 0.812   |
| Cancer recurrence                     | 17 (62.96%)                        | 44 (81.48%)                 |         |
| Miscellaneous – cancer recurrence and liver failure | 1 (3.7%) | 1 (1.85%) |         |
| Hepatic failure or multiple systemic organ dysfunction syndrome during the 90 days after surgery | 0 (0%) | 1 (1.85%) |         |
| Anti-virus therapy:                   |                                    |                             | 0.744   |
| Yes                                   | 24 (88.89%)                        | 46 (85.19%)                 |         |
| No                                    | 3 (11.11%)                         | 8 (14.81%)                  |         |

AFP – α-fetoprotein, BCLC – Barcelona Clinic Liver Cancer staging classification, ECOG – Eastern Cooperative Oncology Group, HCC – hepatocellular carcinoma, HBV – hepatitis B virus, SD – standard deviation.
liver function. There were no significant differences in mean tumor size, number of tumors, serum α-fetoprotein (AFP) concentrations measured before surgery, Eastern Cooperative Oncology Group (ECOG) performance status, distribution of cancer stages, or anti-virus therapy (all $p > 0.05$).

The median duration of sorafenib treatment in the surgery + sorafenib group was 7.3 months (95% CI: 5.8–8.9 months). No patient died within 30 days of resection, although 1 patient in the surgery-only group died within 90 days of resection.

During the 90 days after surgery, 17 patients in the surgery + sorafenib group died due to cancer recurrence, 1 due to miscellaneous cancer recurrence and liver failure, and 1 due to hepatic failure or multiple systemic organ dysfunction syndrome. No significant differences in cause of death were found between the surgery + sorafenib group and surgery-only group. Twenty-four patients received anti-viral therapy in the surgery + sorafenib group, and no significant difference was found between the two groups in this parameter (Table I).

Compared between treatments in overall survival and time to recurrence

The median follow-up duration in the total patient population was 14.5 months (range: 2.6–44.7 months). During this period, 63 deaths occurred (45 in the surgery-only group and 18 in the surgery + sorafenib group). Overall survival rates were significantly higher in the surgery + sorafenib group than in the surgery-only group (median survival 18.6 and 11.9 months respectively, $p = 0.014$, Figure 2 A).

Time to recurrence for the 2 treatments is shown in Figure 3. There was no significant difference between the sorafenib + surgery and the surgery-only groups in time to recurrence ($p = 0.291$).

**Subgroup analysis of overall survival**

In univariate analyses, age and treatment group were found to be significantly related to overall survival (Table II). The risk of death was significantly decreased in the surgery + sorafenib group compared with the surgery-only group (HR = 0.51, $p = 0.016$) and was slightly, but significantly, decreased as age increased (HR = 0.97, $p = 0.035$). When factors significantly related to overall survival in the univariate analyses were included in the multivariate analysis (Table II), after adjustment for age, the risk of death was again significantly decreased in the surgery + sorafenib group compared with the surgery-only group (HR = 0.52, $p = 0.019$).
Overall survival was also related to BCLC stage. For patients in BCLC stage B, overall survival rates were significantly higher in the surgery + sorafenib group than in the surgery-only group (median survival 22.3 and 12.5 months, respectively, \( p = 0.017 \), Figure 2B). For patients in BCLC stage C, no significant difference was found between the two groups in overall survival rate (\( p = 0.199 \), Figure 2C).
Subgroup analysis of time to recurrence

In univariate analyses, only BCLC stage was found to be significantly related to recurrence. The risk of recurrence was significantly increased in BCLC stage C compared to BCLC stage B (HR = 1.64, \( p = 0.045 \)). No other factors were significantly related to recurrence in univariate analysis; therefore multivariate analysis was not performed (Table III).

Relationship between sorafenib and TACE

Equal percentages of patients in the surgery + sorafenib and surgery-only groups received TACE after surgery, 14 (51.9%) in the surgery + sorafenib group and 28 (51.9%) in the surgery only group. Overall survival was similar in those with TACE and those without TACE, both in the patient population as a whole and in patients with either BCLC stage B or stage C (\( p = 0.642 \) in overall survival for the total patient population; \( p = 0.763 \) in overall survival for BCLC stage B; \( p = 0.717 \) in overall survival for BCLC stage C; Figures 4 A–C).

When outcomes for those with and without TACE were examined separately in the 2 treatment groups, there was also no significant difference in overall survival rate (surgery-only group, \( p = 0.746 \) in overall survival; surgery + sorafenib group \( p = 0.067 \) in overall survival) (Figures 5 and 6).

Table III. Univariate analyses to detect factors associated with recurrence

| Parameter                          | Univariate |          |
|------------------------------------|------------|----------|
|                                    | HR (95% CI)| P-value  |
| Age [years]                        | 0.98 (0.95–1) | 0.102    |
| Gender (ref: female)               | 0.73 (0.31–1.7) | 0.468    |
| Viral hepatitis status (ref: unknown) | 0.46 (0.19–1.09) | 0.079    |
| Preoperative AFP (ref: < 400 ng/ml) | 1.02 (0.59–1.74) | 0.957    |
| Liver cirrhosis (ref: no)          | 0.85 (0.48–1.49) | 0.558    |
| ECOG performance status score (ref: 0) | 1.08 (0.66–1.78) | 0.765    |
| BCLC stage (ref: B)                | 1.64 (1.01–2.67) | 0.045*   |
| Number of tumors (ref: < 3)        | 0.9 (0.56–1.44) | 0.654    |
| Tumor size [cm]                    | 0.995 (0.94–1.05) | 0.872    |
| Resection extent (ref: minor)      | 0.87 (0.53–1.43) | 0.581    |
| Tumor differentiation (ref: poor)  | 0.65 (0.39–1.08) | 0.095    |
| TACE therapy (ref: no)             | 1.21 (0.75–1.94) | 0.437    |
| Group (ref: surgery only)          | 0.77 (0.47–1.26) | 0.295    |

Figure 4. A – Overall survival rate between patients with and without TACE. B – Overall survival rate between patients with and without TACE in patients with BCLC stage B. C – Overall survival rate between patients with and without TACE in patients with BCLC stage C.
Tolerability of sorafenib

The overall incidence of treatment-related adverse events was 96.3% in the surgery + sorafenib group and 9.3% in the surgery-only group (Table IV). Significantly higher percentages of patients had hand-foot skin reaction and diarrhea in the surgery + sorafenib group compared with those in the surgery-only group ($p < 0.001$ for hand-foot skin reaction and $p = 0.035$ for diarrhea). There were no significant differences between the two treatments for adverse events of alopecia, rash, hypertension, anorexia, vomiting, nausea, or fatigue (all $p > 0.05$).

Adverse events in patients who received sorafenib were predominantly grade 1 or 2 in severity. Grade 3 adverse events occurred only in those who received sorafenib, and included diarrhea in 1 (3.7%) patient and hand-foot skin reactions in 2 (7.4%) patients. No grade 4 treatment-related adverse events were recorded in either group. Dosage reductions were required in 5 (18.5%) patients in the surgery + sorafenib group due to adverse events, but no patient on sorafenib required treatment discontinuation because of adverse events that caused them to be excluded from the study.

Discussion

In the current study, sorafenib significantly increased overall survival after hepatectomy in patients with intermediate or advanced HCC, but when survival was examined according to cancer stage, this increase reached significance in BCLC B, but not stage C, patients. Almost all patients receiving sorafenib experienced mild adverse effects, the most common being hand-foot skin syndrome. Approximately 50% of patients in both the surgery-only and the surgery + sorafenib group received post-surgery TACE, but the inclusion of TACE did not increase either overall survival or time to recurrence.

Although guidelines recommend hepatectomy only for BCLC stage A patients, current clini-

| Adverse event   | Surgery + sorafenib group (n = 27) | Surgery-only group (n = 54) | $P$-value |
|-----------------|------------------------------------|-----------------------------|-----------|
|                 | Grade 1 | Grade 2 | Grade 3 or 4 | Grade 1 | Grade 2 | Grade 3 or 4 |           |
| HFSR            | 7 (25.9%) | 7 (25.9%) | 2 (7.4%) | 0 (0%) | 0 (0%) | 0 (0%) | < 0.001 |
| Diarrhea        | 4 (14.8%) | 1 (3.7%) | 1 (3.7%) | 2 (3.7%) | 0 (0%) | 0 (0%) | 0.035 |
| Alopecia        | 2 (7.4%) | 1 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.085 |
| Rash            | 4 (14.8%) | 1 (3.7%) | 0 (0%) | 2 (3.7%) | 0 (0%) | 0 (0%) | 0.069 |
| Hypertension    | 1 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.308 |
| Anorexia        | 3 (11.1%) | 0 (0%) | 0 (0%) | 1 (1.85%) | 0 (0%) | 0 (0%) | 0.139 |
| Vomiting        | 1 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.308 |
| Nausea          | 2 (7.4%) | 0 (0%) | 0 (0%) | 1 (1.85%) | 0 (0%) | 0 (0%) | 0.290 |
| Fatigue         | 3 (11.1%) | 0 (0%) | 0 (0%) | 2 (3.7%) | 0 (0%) | 0 (0%) | 0.227 |

HFSR – hand-foot skin reaction.
Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma

In our study, sorafenib increased median effective in younger and older (> 75 years) patients by about 3 months [19, 20] and is equal-of HCC [30]. It prolongs survival in advanced HCC because these patients often have a greater degree of cirrhosis and poorer remaining liver function than patients in earlier stages of HCC, and that increased deaths caused by the worsening liver disease might mask any potential effect of sorafenib on OS.

Sorafenib was well tolerated in our study, and drug-related adverse events reported by patients receiving sorafenib were predominantly only grade 1 or 2 in severity. The most frequent sorafenib-related adverse events in the surgery + sorafenib group were hand-foot skin reactions, which occurred in 17 (63.0%) patients, and diarrhea, which occurred in 6 (22.2%). The incidence of hand-foot skin reactions in our patients was in the middle of the wide range (7% to 100%) reported by others [19, 20, 29, 32, 33]. The incidence of this adverse effect varies with ethnicity, and Asian patients have been reported to have a higher incidence of this syndrome than other groups [20]. It is thought that this is a genetic predisposition due partly to changes in the genes for tumor necrosis factor α (TNF-α) and vascular endothelial growth factor (VEGF) [34]. Also, an increase in the incidence of hand-foot syndrome may be beneficial, since early expression of this and other dermatologic adverse effects has been significantly related to better survival [32, 35–37].

The TACE is currently recommended as the standard treatment for intermediate-stage HCC [38], and has been shown to be superior to supportive treatment in these patients [39–42]. However, TACE has been shown to be inferior to hepatectomy in intermediate-stage HCC [39, 43]. Whether TACE can cause significant improvement when used after hepatectomy is unresolved [44, 45], as is the question of whether it causes significant improvement when added to sorafenib treatment [32, 46–48]. Recently, several investigators have reported that the combination of sorafenib and TACE may be an effective and tolerable treatment strategy for intermediate-stage and advanced HCC. A number of studies, including a systematic review [32, 49–54] of 11 related studies involving 1000 patients, have reported that the sorafenib + TACE combination showed promise as an effective and tolerable treatment strategy. However, these studies did not examine the effects of this combination when used after surgery, and our results show TACE to provide no additional effect on OS or on TTR in either surgery + sorafenib or surgery-only patients.

The current study has several limitations. Firstly, it was a retrospective study and had only a small sample size from a single institute. Most
patients in our study had HBV-related disease, a background that is quite different from that seen in patients in western countries. Another limitation is that the use of TACE may have complicated the efficacy comparisons between the 2 patient groups. However, the TACE/sorafenib combination has previously been found to be an effective treatment, and we matched the use of TACE when selecting patients for the control group.

In conclusion, the present study is the first to demonstrate the efficacy and tolerability of sorafenib therapy following hepatic resection in patients with intermediate-stage and advanced HCC. Our results suggest that adjuvant therapy with sorafenib following liver resection is effective in such patients, especially for intermediate-stage patients. Sorafenib treatment after surgery could therefore be a viable treatment option for these patients. Prospective, multicenter, randomized, controlled studies involving substantially larger patient populations are necessary to confirm our findings.

Acknowledgments

The authors acknowledge the contributions of the other investigators in this trial and Content Ed Net, Shanghai Co. Ltd for editorial assistance during manuscript preparation.

Conflict of interest

The authors declare no conflict of interest.

References

1. International Agency for Research on Cancer (IARC). Available at: http://www-dep.iarc.fr/. Accessed 1 Nov, 2011.
2. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-85.
3. Llovet JM, Brú C, Brux J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
4. EASL-EORTC Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
5. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
7. Llovet JM, Fuster J, Brux J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-20.
8. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the East-West HCC Study Group. Ann Surg 2013; 257: 929-37.
9. Chinese Anti-Cancer Association Society of Liver Cancer, Chinese Society of Clinical Oncology, Chinese Society of Hepatology Liver Cancer Study Group. [The expert consensus on the treatment standards for hepatocellular carcinoma (in Chinese). Dig Dis and Endosc 2009; 3: 40-51.
10. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-64.
11. Korean Liver Cancer Study Group. National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009; 15: 391-423.
12. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-74.
13. Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol 2011; 137: 139-49.
14. Morris-Stiff G, Gomez D, de Liguori Carino N, Prasad KR. Surgical management of hepatocellular carcinoma: is the jury still out? Surg Oncol 2009; 18: 298-321.
15. Chirica M, Scatton O, Massault P, et al. Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery? Arch Surg 2008; 143: 538-43.
16. Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 2008; 143: 1082-90.
17. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-16.
18. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 833-44.
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
20. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events, v3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (2006).
22. Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 302-10.
23. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatotomies without mortality in 8 years. Arch Surg 2003; 138: 1198-206.
24. Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984-92.
25. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-30.
26. Ng KK, Vauthay JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12: 364-73.
27. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140: 450-7.

28. Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 2014; 260: 329-40.

29. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer 2008; 44: 1000-6.

30. Yue Y, Yang Y, Shi L, Wang Z. Suppression of human hepatocellular cancer cell proliferation by Brucea javanica oil-loaded liposomes via induction of apoptosis. Arch Med Sci 2011; 11: 856-62.

31. Nishikawa H, Takeda H, Tsuchiya K, et al. Japanese Red Cross Study Group. Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma. Clinical outcome and safety in aged patients: a multicenter study in Japan. J Cancer 2014; 5: 499-509.

32. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-27.

33. Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcomes in HCC patients treated with sorafenib. J Hepatol 2014; 61: 318-24.

34. Lee JH, Chung YH, Kim JA, et al. Genetic predisposition to hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013; 119: 136-42.

35. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.

36. Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42: 879-86.

37. Di Costanzo GG, Tortora R, Iodice L, et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis 2012; 44: 788-92.

38. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.

39. Roayaie S. TACE vs. surgical resection for BCLC stage B HCC. J Hepatol 2014; 61: 3-4.

40. Llovet JM, Real MI, Montañá X, et al. Arterial embolisation or chemoembolisation versus supportive treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.

41. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.

42. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.

43. Yin L, Li H, Li AL, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol 2014; 61: 82-8.

44. Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol 2014; 49: 449-61.